Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Enzyme therapy for functional bowel disease-like post-prandial distress.

Graham DY, Ketwaroo GA, Money ME, Opekun AR.

J Dig Dis. 2018 Nov;19(11):650-656. doi: 10.1111/1751-2980.12655. Epub 2018 Sep 21. Review.

PMID:
30101562
2.

13C-Labeled-Starch Breath Test in Congenital Sucrase-isomaltase Deficiency.

Robayo-Torres CC, Diaz-Sotomayor M, Hamaker BR, Baker SS, Chumpitazi BP, Opekun AR, Nichols BL.

J Pediatr Gastroenterol Nutr. 2018 Jun;66 Suppl 3:S61-S64. doi: 10.1097/MPG.0000000000001858.

3.

Demographic and Clinical Correlates of Mucosal Disaccharidase Deficiencies in Children With Functional Dyspepsia.

Chumpitazi BP, Robayo-Torres CC, Tsai CM, Opekun AR, Baker SS, Nichols BL, Gilger MA.

J Pediatr Gastroenterol Nutr. 2018 Jun;66 Suppl 3:S52-S55. doi: 10.1097/MPG.0000000000001859.

4.

Brief report: Lactobacillus bulgaricus GLB44 (Proviotic ) plus esomeprazole for Helicobacter pylori eradication: A pilot study.

Opekun AR, Gonzales SA, Al-Saadi MA, Graham DY.

Helicobacter. 2018 Apr;23(2):e12476. doi: 10.1111/hel.12476. Epub 2018 Mar 4.

PMID:
29504209
5.

Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis.

Mindikoglu AL, Opekun AR, Mitch WE, Magder LS, Christenson RH, Dowling TC, Weir MR, Seliger SL, Howell CD, Raufman JP, Rana A, Goss JA, Khaderi SA, Vierling JM.

Dig Dis Sci. 2018 Mar;63(3):665-675. doi: 10.1007/s10620-017-4897-z. Epub 2018 Feb 1.

6.

Traditional Malian Solid Foods Made from Sorghum and Millet Have Markedly Slower Gastric Emptying than Rice, Potato, or Pasta.

Cisse F, Erickson DP, Hayes AMR, Opekun AR, Nichols BL, Hamaker BR.

Nutrients. 2018 Jan 26;10(2). pii: E124. doi: 10.3390/nu10020124.

7.

Impact of Time-Restricted Feeding and Dawn-to-Sunset Fasting on Circadian Rhythm, Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease.

Mindikoglu AL, Opekun AR, Gagan SK, Devaraj S.

Gastroenterol Res Pract. 2017;2017:3932491. doi: 10.1155/2017/3932491. Epub 2017 Nov 19. Review.

8.

Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis.

Mindikoglu AL, Opekun AR, Putluri N, Devaraj S, Sheikh-Hamad D, Vierling JM, Goss JA, Rana A, Sood GK, Jalal PK, Inker LA, Mohney RP, Tighiouart H, Christenson RH, Dowling TC, Weir MR, Seliger SL, Hutson WR, Howell CD, Raufman JP, Magder LS, Coarfa C.

Transl Res. 2018 May;195:25-47. doi: 10.1016/j.trsl.2017.12.002. Epub 2017 Dec 12.

9.

Improved Starch Digestion of Sucrase-deficient Shrews Treated With Oral Glucoamylase Enzyme Supplements.

Nichols BL, Avery SE, Quezada-Calvillo R, Kilani SB, Lin AH, Burrin DG, Hodges BE, Chacko SK, Opekun AR, Hindawy ME, Hamaker BR, Oda SI.

J Pediatr Gastroenterol Nutr. 2017 Aug;65(2):e35-e42. doi: 10.1097/MPG.0000000000001561.

PMID:
28267073
10.

Use of the Biphasic (13)C-Sucrose/Glucose Breath Test to Assess Sucrose Maldigestion in Adults with Functional Bowel Disorders.

Opekun AR, Balesh AM, Shelby HT.

Biomed Res Int. 2016;2016:7952891. doi: 10.1155/2016/7952891. Epub 2016 Aug 8.

11.

Replication of human noroviruses in stem cell-derived human enteroids.

Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U, Tenge VR, Neill FH, Blutt SE, Zeng XL, Qu L, Kou B, Opekun AR, Burrin D, Graham DY, Ramani S, Atmar RL, Estes MK.

Science. 2016 Sep 23;353(6306):1387-1393. Epub 2016 Aug 25.

12.

Human Intestinal Enteroids: a New Model To Study Human Rotavirus Infection, Host Restriction, and Pathophysiology.

Saxena K, Blutt SE, Ettayebi K, Zeng XL, Broughman JR, Crawford SE, Karandikar UC, Sastri NP, Conner ME, Opekun AR, Graham DY, Qureshi W, Sherman V, Foulke-Abel J, In J, Kovbasnjuk O, Zachos NC, Donowitz M, Estes MK.

J Virol. 2015 Oct 7;90(1):43-56. doi: 10.1128/JVI.01930-15. Print 2016 Jan 1.

13.

Serological Correlates of Protection against a GII.4 Norovirus.

Atmar RL, Bernstein DI, Lyon GM, Treanor JJ, Al-Ibrahim MS, Graham DY, Vinjé J, Jiang X, Gregoricus N, Frenck RW, Moe CL, Chen WH, Ferreira J, Barrett J, Opekun AR, Estes MK, Borkowski A, Baehner F, Goodwin R, Edmonds A, Mendelman PM.

Clin Vaccine Immunol. 2015 Aug;22(8):923-9. doi: 10.1128/CVI.00196-15. Epub 2015 Jun 3.

14.

MicroRNA signatures differentiate Crohn's disease from ulcerative colitis.

Schaefer JS, Attumi T, Opekun AR, Abraham B, Hou J, Shelby H, Graham DY, Streckfus C, Klein JR.

BMC Immunol. 2015 Feb 10;16:5. doi: 10.1186/s12865-015-0069-0.

15.

Mucosal and Cellular Immune Responses to Norwalk Virus.

Ramani S, Neill FH, Opekun AR, Gilger MA, Graham DY, Estes MK, Atmar RL.

J Infect Dis. 2015 Aug 1;212(3):397-405. doi: 10.1093/infdis/jiv053. Epub 2015 Jan 29.

16.

Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity.

Czakó R, Atmar RL, Opekun AR, Gilger MA, Graham DY, Estes MK.

Clin Vaccine Immunol. 2015 Feb;22(2):221-8. doi: 10.1128/CVI.00516-14. Epub 2014 Dec 24.

17.

Reply to Kirby et al.

Atmar RL, Opekun AR, Estes MK, Graham DY.

J Infect Dis. 2015 Jan 1;211(1):167. doi: 10.1093/infdis/jiu382. Epub 2014 Jul 10. No abstract available.

18.

Dissecting the cell to nucleus, perinucleus and cytosol.

Shaiken TE, Opekun AR.

Sci Rep. 2014 May 12;4:4923. doi: 10.1038/srep04923.

19.

Determination of the 50% human infectious dose for Norwalk virus.

Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, Ramani S, Hill H, Ferreira J, Graham DY.

J Infect Dis. 2014 Apr 1;209(7):1016-22. doi: 10.1093/infdis/jit620. Epub 2013 Nov 18.

20.

Congenital sucrase-isomaltase deficiency: summary of an evaluation in one family.

Chumpitazi BP, Robayo-Torres CC, Opekun AR, Nichols BL Jr, Naim HY.

J Pediatr Gastroenterol Nutr. 2012 Nov;55 Suppl 2:S36. doi: 10.1097/01.mpg.0000421409.65257.fc. No abstract available.

21.

Poor starch digestion in children with CSID and recurrent abdominal pain.

Robayo-Torres CC, Baker SS, Chumpitazi BP, Lecea CE, Nichols BL Jr, Opekun AR.

J Pediatr Gastroenterol Nutr. 2012 Nov;55 Suppl 2:S32-4. doi: 10.1097/01.mpg.0000421407.88128.5c. No abstract available.

PMID:
23103649
22.

Research progress reported at the 50th Anniversary of the Discovery of Congenital Sucrase-Isomaltase Deficiency Workshop.

Gilger M, Hamaker B, Nichols BL Jr, Auricchio S, Treem WR, Naim HY, Heine M, Zimmer KP, Jones K, Eskandari R, Pinto BM, Rose DR, Lee BH, Quezada-Calvillo R, Adams B, Roach CM, Ma CX, Baker SS, Slawson MH, Robayo-Torres CC, Chumpitazi BP, Lecea CE, Opekun AR, Uhrich S, Wu Z, Huang JY, Scott CR, Chumpitazi BP, McMeans AR, Scholz D, Shulman RJ, Ao Z, Sterchi EE, Lin AH.

J Pediatr Gastroenterol Nutr. 2012 Nov;55 Suppl 2:S1. doi: 10.1097/01.mpg.0000422151.38401.69. No abstract available.

23.

Antibody responses to norovirus genogroup GI.1 and GII.4 proteases in volunteers administered Norwalk virus.

Ajami NJ, Barry MA, Carrillo B, Muhaxhiri Z, Neill FH, Prasad BV, Opekun AR, Gilger MA, Graham DY, Atmar RL, Estes MK.

Clin Vaccine Immunol. 2012 Dec;19(12):1980-3. doi: 10.1128/CVI.00411-12. Epub 2012 Oct 3.

24.

Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus.

Czakó R, Atmar RL, Opekun AR, Gilger MA, Graham DY, Estes MK.

Clin Vaccine Immunol. 2012 Feb;19(2):284-7. doi: 10.1128/CVI.05592-11. Epub 2011 Dec 21.

25.

Norovirus vaccine against experimental human Norwalk Virus illness.

Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, Mendelman PM.

N Engl J Med. 2011 Dec 8;365(23):2178-87. doi: 10.1056/NEJMoa1101245.

26.

Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay.

Kavanagh O, Estes MK, Reeck A, Raju RM, Opekun AR, Gilger MA, Graham DY, Atmar RL.

Clin Vaccine Immunol. 2011 Jul;18(7):1187-90. doi: 10.1128/CVI.00039-11. Epub 2011 May 18.

27.

Serological correlate of protection against norovirus-induced gastroenteritis.

Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, Graham DY, Atmar RL.

J Infect Dis. 2010 Oct 15;202(8):1212-8. doi: 10.1086/656364.

28.

Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States.

Graham DY, Javed SU, Keihanian S, Abudayyeh S, Opekun AR.

J Gastroenterol. 2010 Aug;45(8):816-20. doi: 10.1007/s00535-010-0220-x. Epub 2010 Mar 2.

PMID:
20195646
29.

Rising incidence of inflammatory bowel disease among children: a 12-year study.

Malaty HM, Fan X, Opekun AR, Thibodeaux C, Ferry GD.

J Pediatr Gastroenterol Nutr. 2010 Jan;50(1):27-31. doi: 10.1097/MPG.0b013e3181b99baa.

PMID:
19934770
30.

Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection.

Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY.

Clin Gastroenterol Hepatol. 2010 Jan;8(1):36-41.e1. doi: 10.1016/j.cgh.2009.09.030. Epub 2009 Oct 3.

31.

13C-breath tests for sucrose digestion in congenital sucrase isomaltase-deficient and sacrosidase-supplemented patients.

Robayo-Torres CC, Opekun AR, Quezada-Calvillo R, Villa X, Smith EO, Navarrete M, Baker SS, Nichols BL.

J Pediatr Gastroenterol Nutr. 2009 Apr;48(4):412-8.

32.

Urea breath test in children: the United States prospective, multicenter study.

Elitsur Y, Tolia V, Gilger MA, Reeves-Garcia J, Schmidt-Sommerfeld E, Opekun AR, El-Zimaity H, Graham DY, Enmei K.

Helicobacter. 2009 Apr;14(2):134-40. doi: 10.1111/j.1523-5378.2009.00670.x.

PMID:
19298341
33.

Norwalk virus shedding after experimental human infection.

Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, Graham DY.

Emerg Infect Dis. 2008 Oct;14(10):1553-7. doi: 10.3201/eid1410.080117.

34.

Contribution of mucosal maltase-glucoamylase activities to mouse small intestinal starch alpha-glucogenesis.

Quezada-Calvillo R, Robayo-Torres CC, Opekun AR, Sen P, Ao Z, Hamaker BR, Quaroni A, Brayer GD, Wattler S, Nehls MC, Sterchi EE, Nichols BL.

J Nutr. 2007 Jul;137(7):1725-33.

PMID:
17585022
35.

Visualization of the small intestine using capsule endoscopy in healthy subjects.

Shiotani A, Opekun AR, Graham DY.

Dig Dis Sci. 2007 Apr;52(4):1019-25. Epub 2007 Feb 16.

PMID:
17380402
36.

Two familial cases of high blood galactose of unknown aetiology.

Brunetti-Pierri N, Opekun AR, Craigen WJ.

J Inherit Metab Dis. 2006 Dec;29(6):762. Epub 2006 Sep 21.

PMID:
16988899
37.

Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection.

Graham DY, Abudayyeh S, El-Zimaity HM, Hoffman J, Reddy R, Opekun AR.

Aliment Pharmacol Ther. 2006 Sep 1;24(5):845-50.

38.

Point-of-care Helicobacter pylori urine antibody detection in a multi-ethnic adult population in the United States.

Opekun AR, Luu P, Gotschall AB, Abdalla N, Torres E, Rudd SB, Graham DY, Nurgalieva ZZ, Tsuchiya K.

Transl Res. 2006 Jul;148(1):13-8.

PMID:
16887493
39.

Problem of distinguishing false-positive tests from acute or transient Helicobacter pylori infections.

Nurgalieva ZZ, Opekun AR, Graham DY.

Helicobacter. 2006 Apr;11(2):69-74. Erratum in: Helicobacter. 2006 Jun;11(3):215. Nugalieva, Zhannat Z [corrected to Nurgalieva, Zhannat Z].

PMID:
16579835
40.

Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America.

Graham DY, Nurgalieva ZZ, El-Zimaity HM, Opekun AR, Campos A, Guerrero L, Chavez A, Cardenas V.

Clin Gastroenterol Hepatol. 2006 Mar;4(3):306-14.

PMID:
16527693
41.

Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border.

Cardenas VM, Graham DY, El-Zimaity HM, Opekun AR, Campos A, Chavez A, Guerrero L.

Aliment Pharmacol Ther. 2006 Jan 15;23(2):295-301.

42.

In vivo tests of natural therapy, Tibetan yogurt or fresh broccoli, for Helicobacter pylori infection.

Opekun AR, Yeh CW, Opekun JL, Graham DY.

Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):327-9.

PMID:
16082421
43.

Improved infrared spectrophotometer for point-of-care patient 13C-urea breath testing in the primary care setting.

Opekun AR, Gotschall AB, Abdalla N, Agent C, Torres E, Sutton FM, Graham DY, Tsuchiya K.

Clin Biochem. 2005 Aug;38(8):731-4.

PMID:
15963485
44.

Effect of different organic acids (citric, malic and ascorbic) on intragastric urease activity.

Agha A, Opekun AR, Abudayyeh S, Graham DY.

Aliment Pharmacol Ther. 2005 May 1;21(9):1145-8.

45.

B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans.

Nurgalieva ZZ, Conner ME, Opekun AR, Zheng CQ, Elliott SN, Ernst PB, Osato M, Estes MK, Graham DY.

Infect Immun. 2005 May;73(5):2999-3006.

46.

Practical rapid, minimally invasive, reliable nonendoscopic method to obtain Helicobacter pylori for culture.

Graham DY, Kudo M, Reddy R, Opekun AR.

Helicobacter. 2005 Feb;10(1):1-3.

PMID:
15691309
47.

Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori.

Graham DY, Opekun AR, Belson G, El-Zimaity HM, Carlson MR.

Aliment Pharmacol Ther. 2005 Jan 15;21(2):165-8.

48.

Visible small-intestinal mucosal injury in chronic NSAID users.

Graham DY, Opekun AR, Willingham FF, Qureshi WA.

Clin Gastroenterol Hepatol. 2005 Jan;3(1):55-9.

PMID:
15645405
49.

Challenge model for Helicobacter pylori infection in human volunteers.

Graham DY, Opekun AR, Osato MS, El-Zimaity HM, Lee CK, Yamaoka Y, Qureshi WA, Cadoz M, Monath TP.

Gut. 2004 Sep;53(9):1235-43.

50.

False negative urea breath tests with H2-receptor antagonists: interactions between Helicobacter pylori density and pH.

Graham DY, Opekun AR, Jogi M, Yamaoka Y, Lu H, Reddy R, El-Zimaity HM.

Helicobacter. 2004 Feb;9(1):17-27.

PMID:
15156900

Supplemental Content

Loading ...
Support Center